Cempra (CEMP) : Zacks Investment Research ranks Cempra (CEMP) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 1.25, which indicates as a Strong Buy.
Cempra (CEMP) has been rated by 9 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $51 and the lowest price target forecast is $25. The average forecast of all the analysts is $39.22 and the expected standard deviation is $7.6.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Cempra (NASDAQ:CEMP). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Jefferies lowers the price target from $42 per share to $40 per share. The rating by the firm was issued on August 2, 2016.
Cempra (NASDAQ:CEMP): stock was range-bound between the intraday low of $22.58 and the intraday high of $23.53 after having opened at $22.87 on Wednesdays session. The stock finally closed in the red at $22.87, a loss of -0.31%. The stock remained in the red for the whole trading day. The total traded volume was 578,727 shares. The stock failed to cross $23.53 in Wednesdays trading. The stocks closing price on Thursday was $22.83.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.